BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors-Reference-Cited by-同舟云学术

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Published:2018-08 Issue:8 Volume:13 Page:1128-1137
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Dudnik Elizabeth,Peled Nir,Nechushtan Hovav,Wollner Mira,Onn Amir,Agbarya Abed,Moskovitz Mor,Keren Shoshana,Popovits-Hadari Noa,Urban Damien,Mishaeli Moshe,Zer Alona,Allen Aaron M.,Rabinovich Natalie Maimon,Rotem Ofer,Kuznetsov Teodor,Shochat Tzippy,Roisman Laila C.,Bar Jair

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations;Paik;J Clin Oncol,2011

2. Clinical features and outcome of patients with non–small-cell lung cancer harboring BRAF mutations;Marchetti;J Clin Oncol,2011

3. Clinical, pathologic, and biologic features associated with BRAF mutations in non–small cell lung cancer;Cardarella;Clin Cancer Res,2013

4. BRAF mutations in patients with non–small cell lung cancer: a systematic review and meta-analysis;Chen;PLoS ONE,2014

5. Mechanism of activation of the RAF–ERK signaling pathway by oncogenic mutations of B-RAF;Wan;Cell,2004

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways;Cytokine & Growth Factor Reviews;2024-10

2. Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study;Future Oncology;2024-09-03

3. In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma;Cell Reports Medicine;2024-08

4. Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non–Small Cell Lung Cancer;JCO Precision Oncology;2024-08

5. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC;Lung Cancer;2024-08